Terbinafine hydrochloride is under clinical development by Moberg Pharma and currently in Phase III for Onychomycosis (Tinea Unguium). According to GlobalData, Phase III drugs for Onychomycosis (Tinea Unguium) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Terbinafine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Terbinafine hydrochloride overview
Terbinafine hydrochloride (Terclara) is a synthetic allylamine antifungal agent. It is formulated as solution for topical and cutaneous application. It is indicated for the treatment of onychomycosis (nail fungus).
Terbinafine (MOB-015) is under development for the treatment of onychomycosis. The drug candidate is applied topically. It is an allylamine fungicidal agent. It targets squalene epoxidase.
Moberg Pharma overview
Moberg Pharma is a pharmaceutical company primarily focused on the development and improvement of dermatological treatments. The company’s lead product is MOB-015, a patented formulation technology that facilitates the delivery of high concentrations of the antifungal substance terbinafine through the nail, used for the treatment of nail fungus. This product is marketed under the brand name Terclara. Moberg Pharma’s products are primarily used by individuals suffering from mild to moderate nail fungus on fingernails and toenails. The company markets its products in Europe, South America and Africa. Moberg Pharma is headquartered in Stockholm, Sweden.
For a complete picture of Terbinafine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
